Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:57:25.561Z.
Calculation as of: 2026-10-06T16:57:25.561Z.
Quote observation: 2026-10-06T16:55:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: acb65a17080c98cb556e8dedfcd99ff418fc0d96cba63b9d245ba9f7ac680701
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$12.37M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.78M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.61M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.46M
Price/OCF Ratio
N/A
TTM Avg
6.96
3Y Avg
6.96
5Y Avg
6.96
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | $12.44M | N/A | N/A | N/A | N/A |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.37M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.57M | N/A | 3.83 | 3.83 | 3.83 |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A | 9.81 | 9.81 | 9.81 |
| Cytosorbents Corporation (CTSO)vs › | $12.77M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.78M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.24M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.61M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.46M | N/A | 6.96 | 6.96 | 6.96 |
| Biofrontera Inc. (BFRI)vs › | $11.45M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
